GSK plc

LONDON, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 5, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$497.0M2026 Q3
Positions13
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.98.1%

GSK plc reported 13 positions worth $497.0M as of September 30, 2026 (13F filed November 5, 2026). Largest holding: CRSP (29.0%). Biggest move: exit 96663EUR ($106.0M).

10 / 13 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 CRSPCRISPR Therapeutics$144.3M29.03%2,608,419——-23.6%
▸ 2 VIRVir Biotechnology$95.6M19.23%8,550,954——-10.9%
▸ 3 WVEWave Life Sciences$67.5M13.58%18,245,691——-15.4%
▸ 4 BNTXBioNTech$65.7M13.22%668,526——-12.9%
▸ 5 IDYAIDEAYA Biosciences$51.2M10.31%1,333,333——-17.2%
▸ 6 CYTKCytokinetics$22.4M4.51%340,434——-14.8%
▸ 7 LYELLyell Immunopharma$14.8M2.98%1,512,659——+46.1%
▸ 8 SPROSpero Therapeutics$11.1M2.24%9,190,606——-17.4%
▸ 9 NKTXNkarta$8.3M1.66%3,150,732———
▸ 10 FULCFulcrum Therapeutics$6.6M1.33%1,785,714——-1.4%

Pro Feature

The remaining 3 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does GSK plc hold as of Q3 2026?

GSK plc reported 13 positions worth $497.0M in its Q3 2026 13F filing. Largest positions: CRSP (29.0%), VIR (19.2%), WVE (13.6%), BNTX (13.2%) and IDYA (10.3%).

What did GSK plc buy in Q3 2026?

New positions: WVE.

What did GSK plc sell in Q3 2026?

Reduced: CRSP and BNTX. Sold out entirely: 96663EUR.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.